Amgen (AMGN) : Boston Advisors reduced its stake in Amgen by 3.56% during the most recent quarter end. The investment management company now holds a total of 456,478 shares of Amgen which is valued at $74,492,645 after selling 16,866 shares in Amgen , the firm said in a disclosure report filed with the SEC on Apr 20, 2016.Amgen makes up approximately 1.82% of Boston Advisors’s portfolio.
Amgen closed down -1.16 points or -0.71% at $163.19 with 27,57,177 shares getting traded on Friday. Post opening the session at $164.52, the shares hit an intraday low of $162.18 and an intraday high of $164.7 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Other Hedge Funds, Including , Murphy Pohlad Asset Management boosted its stake in AMGN in the latest quarter, The investment management firm added 260 additional shares and now holds a total of 1,538 shares of Amgen which is valued at $250,986. Amgen makes up approx 0.19% of Murphy Pohlad Asset Management’s portfolio.Signature Estate Investment Advisors reduced its stake in AMGN by selling 73,446 shares or 96.44% in the most recent quarter. The Hedge Fund company now holds 2,714 shares of AMGN which is valued at $434,593. Amgen makes up approx 0.07% of Signature Estate Investment Advisors’s portfolio.Gofen Glossberg Il boosted its stake in AMGN in the latest quarter, The investment management firm added 149 additional shares and now holds a total of 21,114 shares of Amgen which is valued at $3,380,985. Amgen makes up approx 0.14% of Gofen Glossberg Il’s portfolio.First United Bank Trust boosted its stake in AMGN in the latest quarter, The investment management firm added 745 additional shares and now holds a total of 6,398 shares of Amgen which is valued at $1,024,512. Amgen makes up approx 0.93% of First United Bank Trust’s portfolio.Weaver C. Barksdale Associates reduced its stake in AMGN by selling 33 shares or 0.63% in the most recent quarter. The Hedge Fund company now holds 5,200 shares of AMGN which is valued at $813,228. Amgen makes up approx 0.61% of Weaver C. Barksdale Associates’s portfolio.
On the company’s financial health, Amgen reported $2.61 EPS for the quarter, beating the analyst consensus estimate by $ 0.32 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $2.29. The company had revenue of $5536.00 million for the quarter, compared to analysts expectations of $5534.94 million. The company’s revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.16 EPS.
Investors should note that on Mar 2, 2016, Amgen announced a cash dividend of $1.0000. The company’s management has announced May 13, 2016 as the ex-dividend date and fixed the record date on May 17, 2016. The payable date has been fixed on Jun 8, 2016.
Many Wall Street Analysts have commented on Amgen. Citigroup Initiated Amgen on Feb 25, 2016 to “Neutral”, Price Target of the shares are set at $165.Shares were Reiterated by Argus on Feb 8, 2016 to “Buy” and Lowered the Price Target to $ 185 from a previous price target of $202 .
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.